Company intelligence / Profile preview

Medi-Tate

Or Akiva/Hadera, Haifa, Israelolympus-global.com ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Medi-Tate’s flagship product, the iTind device, is a minimally invasive temporary implant that reshapes the prostatic urethra to relieve lower urinary tract symptoms caused by BPH. Clinical studies have shown significant and durable symptom relief lasting more than four years post-treatment. The procedure has demonstrated improvements in International Prostate Symptom Score (IPSS) and quality of life with low surgical re-treatment rates over long-term follow-up.

Therapeutic areas: Men's Health
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

Olympus Corporation was both distributor and later acquirer

Beyond the preview

Go deeper on Medi-Tate.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Medi-Tate.

Explore the full profile